Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2011 Results
Date:11/4/2011

ROCKVILLE, Md., Nov. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

"We are excited with our progress this quarter and especially as it relates to our efforts on tasimelteon," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer.  "Our programs for both Non-24-Hour Sleep-Wake Disorder and Major Depression continue to move Vanda forward towards our goal of becoming a global leader in the field of chronobiology and the treatment of circadian rhythm disorders."

Key Highlights:

  • Vanda recorded third quarter 2011 revenue of $8.0 million including royalties of $1.2 million. Fanapt® prescriptions, as reported by IMS, reached 33,000 in the third quarter of 2011.  This represents a 10% increase over second quarter 2011 prescriptions.  
  • The tasimelteon Non-24-Hour Sleep-Wake Disorder (N24HSWD or Non-24) program continues to advance with two new studies initiated to support registration and is on track for a mid 2013 New Drug Application (NDA) filing.
  • The tasimelteon Major Depressive Disorder (MDD) Phase IIb/III study (MAGELLAN) was initiated in September 2011.  Vanda expects to report results from the MAGELLAN study in the first half of 2013.
  • On October 24, 2011, Vanda announced that Bob Repella joined its management team as Senior Vice President, Chief Commercial Officer.

  • THIRD QUARTER 2011 REPORTED RESULTSTotal revenues for the third quarter of 2011 were $8.0 million, compared to $7.2 million for the same period in 2010. Third quarter 2011 revenues included $1.2 million related t
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Appoints Chief Commercial Officer
    2. Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
    3. Vanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
    4. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
    6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanaptâ„¢ in Mexico
    7. Vanda Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    8. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
    9. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
    10. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
    11. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... -- Today, in final recognition of the Centers for Disease ... Contacts is sharing how to keep lens cases clean.  ... do not properly care for their lens cases are ... Most contact lens wearers understand the importance of ... is sometimes overlooked.  When proper steps to clean a ...
    (Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
    (Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
    Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
    ... March 25, 2007 /PRNewswire/ -- Once-daily,dosing with ... antagonist, was associated with improvements,in signs and ... hospitalized patients receiving conventional care, without an,adverse ... These,data are from the short- and long-term ...
    ... BETHESDA, Md., March 26, 2007--Having a build-up of ... heart attacks and,death from heart disease in multiple ... Study of Atherosclerosis (MESA),funded by the National Heart, ... Health. Previous studies have shown that,increased coronary artery ...
    Cached Medicine Technology:Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2
    (Date:8/29/2015)... Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Pro X . Each preset contains 15 seconds of unique footage that users can ... that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, ...
    (Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
    (Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
    (Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
    Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
    ... DALLAS, Nov. 20 Crdentia Corp. (OTC Bulletin,Board: ... the,promotion of Ms. Penny Kirsch to Vice President ... Human Resources Manager,for Crdentia and will continue to ... Kirsch will be responsible for all human resources ...
    ... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials company ... delivery products, today,announced that President and CEO Robert P. ... Annual Healthcare Conference at the Palace,Hotel in New York ... EST. Lazard Capital Markets will host a web ...
    ... System Included in Molecular Imaging Zone, FORT ... (OTC Bulletin Board: IMDS) a pioneer in laser,optical ... will,feature breast cancer cases imaged with optical computed ... November 25 - 28. A CT,Laser Mammography (CTLM(R)) ...
    ... today the pricing of its public offering of 1,466,400 ... $3.50 per share. Uroplasty,has granted the underwriters a 30-day ... common stock at the offering price to cover,over-allotments. The ... to expand its sales and marketing organization in the ...
    ... save children,s lives runs through December 8 in all 6,200 ... ... be,participating in the fourth year of the St. Jude Children,s Research,Hospital(R) ... December 8. As part of this national,campaign, CVS/pharmacy has joined with ...
    ... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
    Cached Medicine News:Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3Health News:Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 3Health News:Urine Test Results Can Point to Heart Dangers 2
    Flat Wire Stone Basket...
    ... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
    Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
    ... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
    Medicine Products: